ASHLEY LUNDGREN: Open Payments
NPI 1942695192 · SPOKANE, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$500 in 24 payments from 10 companies in 2025. Trend: 2023 $345 · 2024 $436 · 2025 $500
Food & beverage: $500
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 8 | $143 |
| GENZYME CORPORATION | 4 | $101 |
| Galderma Laboratories, L.P. | 3 | $63 |
| ABBVIE INC. | 3 | $52 |
| UCB, Inc. | 1 | $45 |
| Lilly USA, LLC | 1 | $24 |
| Amgen Inc. | 1 | $22 |
| Organon LLC | 1 | $18 |
| Novartis Pharmaceuticals Corporation | 1 | $18 |
| Arcutis Biotherapeutics, Inc. | 1 | $14 |
Products named: TREMFYA, DUPIXENT, NEMLUVIO, RINVOQ, Bimzelx, TALTZ, OTEZLA, COSENTYX.
Industry payments across WA — which companies pay providers there.
